Company intelligence / Profile preview

Shanghai Huidun Bio-Technology Co., Ltd.

Shanghai, Shanghai Shi / Municipality of Shanghai, Chinahuilunbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Shanghai Huidun Bio-Technology has a pipeline focused on biological products and therapeutic vaccines targeting oncology and infectious/immune diseases. Its lead asset, a recombinant EGF–CRM197 therapeutic cancer vaccine for non-small cell lung cancer, has reached Phase 2 clinical trials. The company also has several preclinical programs in neoplasms and other disease areas.

Therapeutic areas: OncologyImmunologyNeurologyInfectious Diseases
Modalities: Biological productsTherapeutic vaccines
Industry: Biotech

Drug pipeline

1 asset

Prodencel

Beyond the preview

Go deeper on Shanghai Huidun Bio-Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Huidun Bio-Technology Co., Ltd..

Explore the full profile